Cargando…

Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4–5

PURPOSE: This study aimed to investigate the clinical outcomes with gemcitabine-carboplatin (GCb), the standard treatment for patients with advanced urothelial carcinoma (UC) who are ineligible for cisplatin-based regimens, in advanced UC patients with a glomerular filtration rate (GFR) < 30 mL/m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung-Don, Im, Hyeon-Su, Kim, Jwa Hoon, Jeong, Hyehyun, Yoon, Shin Kyo, Park, Inkeun, Lee, Jae Lyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524029/ https://www.ncbi.nlm.nih.gov/pubmed/33677847 http://dx.doi.org/10.4143/crt.2021.091

Ejemplares similares

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
por: Park, Inkeun, et al.
Publicado: (2020)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium
por: Xu, Nong, et al.
Publicado: (2007)

Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study
por: Azmy, Aly M., et al.
Publicado: (2012)

Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer
por: Khan, Khurum, et al.
Publicado: (2013)

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
por: Huang, Jiwei, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
por: Mudad, Raja, et al.
Publicado: (2017)

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
por: Choi, Yeonjoo, et al.
Publicado: (2019)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2015)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin – preliminary results
por: Morizane, Shuichi, et al.
Publicado: (2012)

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2016)

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
por: Kitchen, D, et al.
Publicado: (2013)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report
por: Fukuhara, Hiroki, et al.
Publicado: (2017)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
por: Park, Inkeun, et al.
Publicado: (2019)

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
por: Chun, Sang Hoon, et al.
Publicado: (2011)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
por: Lv, Xing, et al.
Publicado: (2016)

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
por: Yang, Rui, et al.
Publicado: (2023)

Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study
por: Boonsong, Thitaya, et al.
Publicado: (2022)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_smjerd68dln70no8bgk9imghk8